162 related articles for article (PubMed ID: 38110219)
1. Initiation of opioid agonist therapy after hospital visits for opioid poisonings in Ontario.
Hu T; McCormack D; Juurlink DN; Campbell TJ; Bayoumi AM; Leece P; Kent JT; Gomes T
CMAJ; 2023 Dec; 195(49):E1709-E1717. PubMed ID: 38110219
[TBL] [Abstract][Full Text] [Related]
2. Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: A population-based time-series analysis.
Kitchen SA; Campbell TJ; Men S; Bozinoff N; Tadrous M; Antoniou T; Wyman J; Werb D; Munro C; Gomes T
Int J Drug Policy; 2022 May; 103():103644. PubMed ID: 35272107
[TBL] [Abstract][Full Text] [Related]
3. Initiating opioid agonist treatment for opioid use disorder nationally in the Veterans Health Administration: Who gets what?
Manhapra A; Stefanovics E; Rosenheck R
Subst Abus; 2020; 41(1):110-120. PubMed ID: 31403914
[No Abstract] [Full Text] [Related]
4. Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation.
Gomes T; Campbell TJ; Kitchen SA; Garg R; Bozinoff N; Men S; Tadrous M; Munro C; Antoniou T; Werb D; Wyman J
JAMA; 2022 Mar; 327(9):846-855. PubMed ID: 35230394
[TBL] [Abstract][Full Text] [Related]
5. Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study.
Russell C; Nafeh F; Pang M; MacDonald SF; Derkzen D; Rehm J; Fischer B
BMC Public Health; 2022 Mar; 22(1):436. PubMed ID: 35246083
[TBL] [Abstract][Full Text] [Related]
6. Neurocognitive, psychiatric, and substance use characteristics in a diverse sample of persons with OUD who are starting methadone or buprenorphine/naloxone in opioid treatment programs.
Scott TM; Arnsten J; Olsen JP; Arias F; Cunningham CO; Rivera Mindt M
Addict Sci Clin Pract; 2021 Oct; 16(1):64. PubMed ID: 34689841
[TBL] [Abstract][Full Text] [Related]
7. Impact of the COVID-19 pandemic on the prevalence of opioid agonist therapy discontinuation in Ontario, Canada: A population-based time series analysis.
Garg R; Kitchen SA; Men S; Campbell TJ; Bozinoff N; Tadrous M; Antoniou T; Wyman J; Werb D; Munro C; Gomes T
Drug Alcohol Depend; 2022 Jul; 236():109459. PubMed ID: 35489179
[TBL] [Abstract][Full Text] [Related]
8. Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study.
Gomes T; McCormack D; Bozinoff N; Tadrous M; Antoniou T; Munro C; Campbell T; Paterson JM; Mamdani M; Sproule B
Addiction; 2022 Jul; 117(7):1972-1981. PubMed ID: 35257434
[TBL] [Abstract][Full Text] [Related]
9. Trends in Rates of Opioid Agonist Treatment and Opioid-Related Deaths for Youths in Ontario, Canada, 2013-2021.
Rosic T; Kolla G; Leece P; Kitchen S; Gomes T
JAMA Netw Open; 2023 Jul; 6(7):e2321947. PubMed ID: 37410463
[TBL] [Abstract][Full Text] [Related]
10. Opioid Use Disorder Treatment Initiation and Continuation: a Qualitative Study of Patients Who Received Addiction Consultation and Hospital-Based Providers.
Calcaterra SL; Lockhart S; Callister C; Hoover K; Binswanger IA
J Gen Intern Med; 2022 Aug; 37(11):2786-2794. PubMed ID: 34981359
[TBL] [Abstract][Full Text] [Related]
11. Opioid agonist therapy switching among individuals with prescription-type opioid use disorder: Secondary analysis of a pragmatic randomized trial.
Mocanu V; Bozinoff N; Wood E; Jutras-Aswad D; Le Foll B; Lim R; Cheol Choi J; Yin Mok W; Eugenia Socias M;
Drug Alcohol Depend; 2023 Jul; 248():109932. PubMed ID: 37224674
[TBL] [Abstract][Full Text] [Related]
12. Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province.
Sadek J; Saunders J
BMC Psychiatry; 2022 Jul; 22(1):516. PubMed ID: 35908052
[TBL] [Abstract][Full Text] [Related]
13. Association Between Hospital Adoption of an Emergency Department Treatment Pathway for Opioid Use Disorder and Patient Initiation of Buprenorphine After Discharge.
Solomon KT; O'Connor J; Gibbons JB; Kilaru AS; Feder KA; Xue L; Saloner B; Stuart EA; Cole ES; Hulsey E; Meisel Z; Patel E; Donohue JM
JAMA Health Forum; 2023 Mar; 4(3):e230245. PubMed ID: 36961457
[TBL] [Abstract][Full Text] [Related]
14. Uptake of slow-release oral morphine as opioid agonist treatment among hospitalised patients with opioid use disorder.
Brothers TD; Fraser J; MacAdam E; Morgan B; Webster D
Drug Alcohol Rev; 2022 Feb; 41(2):430-434. PubMed ID: 34347327
[TBL] [Abstract][Full Text] [Related]
15. Opioid-induced analgesia among persons with opioid use disorder receiving methadone or buprenorphine: A systematic review of experimental pain studies.
De Aquino JP; Parida S; Avila-Quintero VJ; Flores J; Compton P; Hickey T; Gómez O; Sofuoglu M
Drug Alcohol Depend; 2021 Nov; 228():109097. PubMed ID: 34601272
[TBL] [Abstract][Full Text] [Related]
16. The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale.
Socias ME; Ahamad K; Le Foll B; Lim R; Bruneau J; Fischer B; Wild TC; Wood E; Jutras-Aswad D
Contemp Clin Trials; 2018 Jun; 69():21-27. PubMed ID: 29627621
[TBL] [Abstract][Full Text] [Related]
17. Characterizing opioid agonist treatment discontinuation trends in British Columbia, Canada, 2012-2018.
Krebs E; Homayra F; Min JE; MacDonald S; Gold L; Carter C; Nosyk B
Drug Alcohol Depend; 2021 Aug; 225():108799. PubMed ID: 34087747
[TBL] [Abstract][Full Text] [Related]
18. Relationship between choice of opioid agonist therapy and distance from patients' residences in Taiwan, 2012-2014.
Wei LC; Chan HY
Am J Drug Alcohol Abuse; 2021 Sep; 47(5):590-598. PubMed ID: 34402338
[TBL] [Abstract][Full Text] [Related]
19. Twelve-Month Retention in Opioid Agonist Treatment for Opioid Use Disorder Among Patients With and Without HIV.
Wyse JJ; McGinnis KA; Edelman EJ; Gordon AJ; Manhapra A; Fiellin DA; Moore BA; Korthuis PT; Kennedy AJ; Oldfield BJ; Gaither JR; Gordon KS; Skanderson M; Barry DT; Bryant K; Crystal S; Justice AC; Kraemer KL
AIDS Behav; 2022 Mar; 26(3):975-985. PubMed ID: 34495424
[TBL] [Abstract][Full Text] [Related]
20. Rates of opioid agonist treatment prescribing in provincial prisons in Ontario, Canada, 2015-2018: a repeated cross-sectional analysis.
Bodkin C; Bondy S; Regenstreif L; Kiefer L; Kouyoumdjian F
BMJ Open; 2021 Nov; 11(11):e048944. PubMed ID: 34794988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]